DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
— - 1 Emily - 1 Park - 1 Paul Forman - 1 Paul - 1 Forman - 1 Ashley Park - 1 Lily Collins - 1
Top related locs:
Paris Dubai Maldives Evros Greece West Nile Brazil Bangladesh
Top related orgs:
American Thoracic Society - 2 Service - 1 Business - 1 Park Hyatt - 1 Joali - 1 REUTERS - 1 Rights - 1 World Health Organization - 1

Search resuls for: "American Thoracic Society"


4 mentions found


☆ 'Emily in Paris' star Ashley Park says she's recovering from 'critical septic shock' after a bout of tonsillitis
  + stars: | 2024-01-20 | by ( Eve Crosbie | ) www.businessinsider.com   time to read: +2 min
Read previewAshley Park, best known for her roles in "Emily in Paris," "Joy Ride," and "Beef," is recovering in hospital after suffering from septic shock following a bout of tonsillitis. In a post on Instagram on Friday, the actor shared that while on vacation in December, she developed a tonsil infection that "spiraled into critical septic shock, which infected and affected several of my organs." In the post, Park thanked her costar and boyfriend Paul Forman for helping her through "three foreign hospitals, a week in the ICU, scary ERs, countless scans and tests and injections," and "excruciating pain." According to NHS inform, "septic shock is a life-threatening condition that happens when your blood pressure drops to a dangerously low level after an infection." "Emily in Paris" star Lily Collins shared in another Instagram post yesterday that the cast had "reunited" in Paris ready for the show's fourth season.
Persons: —, Emily, Park, Paul Forman, Paul, Forman, Ashley Park, Lily Collins Organizations: Service, Business, American Thoracic Society, Park Hyatt, Joali Locations: Paris, Instagram, Dubai, Maldives
☆ Explainer: How climate change is making the world sick
  + stars: | 2023-12-03 | by ( Gloria Dickie | Thomson Reuters | Gloria Dickie Reports On Climate | ) www.reuters.com   time to read: +5 min
These are just a few of the ways that public health has been impacted and compounded by climate change - a focus for the first time ever at the annual U.N. climate summit COP28. Here's how climate change is harming people's health across the world today, and what countries might expect in the future. Floods in Pakistan last year, for example, led to a 400%increase in malaria cases in the country, the report said. MURKY WATERSStorms and flooding wrought by climate change are allowing other infectious water-borne diseases to proliferate as well. Diarrhoea, too, receives a boost from climate change, with increasingly erratic rainfall - resulting in either wet or dry conditions - yielding a higher risk, research has found.
Persons: Alexandros Avramidis, Martin Edlund, Gloria Dickie, Alexander Cornwall, Katy Daigle, Diane Craft Organizations: REUTERS, Rights, World Health Organization, WHO, Nature Medicine, American Thoracic Society, Reuters, Thomson Locations: Evros, Greece, West Nile, Brazil, Bangladesh, Pakistan, Africa, United States
☆ Sanofi: smoker's lung drug benefit was swift and sustained in trial
  + stars: | 2023-05-22 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
May 22 (Reuters) - The benefits of Sanofi (SASY.PA) and Regeneron's (REGN.O) anti-inflammatory drug Dupixent set in quickly during a trial to treat "smoker's lung" and lasted for the duration of the 1-year study, French drugmaker Sanofi said late on Sunday. The company said it was discussing with major watchdogs across the world whether the trial results are substantial enough to support a regulatory review or whether that will require the results of another ongoing trial. Sanofi presented details on the successful study at the American Thoracic Society congress in Washington over the weekend. "Within two weeks we saw improvement in lung function and improvement in quality of life," said Naimish Patel, Sanofi head of global development for immunology and inflammation. "We will take these results to regulators and have a discussion about what can be done ahead of the read-out of the second trial," Patel said.
☆ Sanofi Q1 profit buoyed by better-than-expected Dupixent sales
  + stars: | 2023-04-27 | by ( Ludwig Burger | ) www.reuters.com   time to read: +2 min
SummarySummary Companies Adj EPS still seen up by "low single digit" percentage in 2023Q1 operating profit, Dupixent sales beat consensusEstablished MS pill Aubagio hit by U.S. generic competitionApril 27 (Reuters) - French drugmaker Sanofi (SASY.PA) on Thursday posted better-than-expected earnings for the first quarter as continued gains from anti-inflammatory drug Dupixent more than offset declining sales from an established multiple sclerosis drug. It reported an 8.7% rise in quarterly business operating income, or adjusted earnings before interest and tax, to 3.33 billion euros ($3.7 billion), ahead of an average analyst estimate of 3.14 billion posted on the company's website. Revenue from eczema and asthma drug Dupixent, jointly developed with Regeneron (REGN.O), surged more than 43% to 2.32 billion euros, above a consensus of 2.27 billion euros. Finance chief Jean-Baptiste de Chatillon said in a media call that, for now, there would be no new annual peak sales estimate for the product, which Sanofi has put at more than 13 billion euros. ($1 = 0.9049 euros)Reporting by Ludwig Burger; Editing by Jacqueline WongOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 4